Ir directamente a la información del producto
1 de 3

Dante ColoAlert - Cribado de última generación para el tumor colorante

Dante ColoAlert - Cribado de última generación para el tumor colorante

Precio habitual €199.00 EUR
Precio habitual Precio de oferta €199.00 EUR
Oferta Agotado

Este producto sólo está disponible para Italia y los EAU

ColoAlert es un test seguro y no invasivo reconocido con la marca CE-IVD. Esta prueba verifica la presencia de un posible cáncer de color en cualquier fase de desarrollo, con un método de recogida del campo totalmente indoloro.

Especialmente para este tipo de patología, en caso de diagnóstico precoz las posibilidades de recuperación de la cura crecen exponencialmente. Pero conseguirlo no es fácil, ya que los síntomas del tumor pueden ser silenciosos en las primeras fases de desarrollo. Por lo tanto, es crucial seguir un plan de prevención eficaz y, al mismo tiempo, compatible con la comodidad.

El test Coloalert es la respuesta a esta necesidad:

  • Se utiliza en el 85% de los casos de cáncer de color y muy a menudo también en las primeras fases de desarrollo, las más difíciles de identificar 1
  • Verifica la presencia de los tumores incluso sin pérdida de emisiones en los tejidos, a través de la lectura del ADN del propio tumor
  • No es invasivo, es indoloro y es rápido (menos de 5 minutos para recoger el campo)
  • Detecta de forma precoz posibles masas tumorales mejor que la prueba de la sangre oculta 1, 2
  • Más del 60% de error en menos en comparación con la prueba inmunocímica fecal (FIT)1,2
    1) Dollinger MM et al. (2018), ClinLab 64(10), 1719-1730.
    2) Gies et al. (2018). Gastroenterología 154(1), 93-104. 3) Cooper GS et al. (2018). Dig Dis Sci. 63(6), 1449-1453.

    Alta tecnología

    A través de
    un análisis del ADN, esta prueba puede detectar tanto la parte del código
    genético humano como la de una posible masa tumoral. De este modo, el laboratorio
    puede verificar la presencia de un tumor en todas sus fases y
    a partir del único campo fecal.

    Privacidad y seguridad

    Diseñado y garantizado por las normas europeas de seguridad y privacidad (GDPR).

    Envío gratuito

    Los gastos de envío son gratuitos, tanto para recibir el kit de recogida como para enviar el campamento al laboratorio.

    Raccolta Campione Indolore

    Para realizar la prueba es necesario encontrar una campana fecal. El proceso es sencillo, no invasivo y no requiere más de 5 minutos.

    Ver todos los detalles

    Next Generation Screening

    • 3 years of coverage

    • 85% Sensitivity *

    • 92% Specificity **

    • Painless and Non Invasive

    • Early Detection

    • +60% efficiency compared to FIT

    1 de 6

    * Sensitivity, ability to correctly identify cases of patients actually suffering from the disease
    ** Specificity, ability to correctly identify cases of patients not affected by the disease

    • Compre y reciba la prueba en la comodidad de su casa

      Free shipping and sending the sample to the lab

    • Enviar gratuitamente el campamento al laboratorio

      Keep your data in order and secure in your personal account

    • Ricevi i risultati a pochi giorni dalla ricezione

      Receive the digital panels signed and commented by the doctor

    El verdadero peligro del cáncer de color

    About 70% of colon cancer cases affect people over the age of 50.
    For those over 50 and for those with a family history of colorectal cancer, it is therefore strongly recommended to follow a constant screening plan and not wait for symptoms to appear.
    Signs such as blood loss in the stool are found mainly in the third and fourth stages of tumor development - the penultimate and last, respectively. In these phases the tumor mass is so extensive that it is damaged by the passage of stools along the intestine, for this reason it is damaged and releases traces of blood.
    Waiting for obvious symptoms to appear has a strong impact not only on the cost of therapies, but also on their chances of success, which are much lower in the last two stages of tumor development than in cases of timely diagnosis.

    1 de 4

    ColoAlert and FIT

    The fecal immunochemical test (FIT) detects the presence of polyps in the intestinal tract that have grown to a cancerous state. These polyps reach such a voluminous mass that they are damaged when the stool passes through the intestine, releasing traces of blood.
    The presence of traces of blood in the stool due to a polyp, therefore, depends on an advanced degree of development of the tumor mass. Furthermore, we must not forget that other problems, unrelated to the presence of a tumor, can also lead to blood loss of this type. Let's think, for example, of intestinal ulcers, hemorrhoids, diverticulosis and more.

    To overcome all these constraints, ColoAlert has been designed with a double analysis:

    • Fecal Occult Blood Test GOLD

      Next Generation version GOLD

      to detect the presence of hemoglobin, and consequently blood, in the stools.

    • DNA Test

      Real Time PCR technology

      Genetic analysis to detect tumor markers and the quantification of human DNA.

    The identification of multiple risk factors allows ColoAlert to overcome the limits connected not only to blood traces dispersed in the stools, but also to all those symptoms that can be confused with other non-pathological problems or problems that cannot be found in the early stages of tumor development.

    ColoAlert and Colonoscopy

    The diagnostic test for identifying colorectal cancer is colonoscopy.
    This exam allows you to receive a real-time picture of the clinical state of the colorectum. Despite the various advantages conferred by this examination, many patients are reluctant to undergo it and it is not chosen for a constant prevention strategy.
    The main frictions are related to the preoperative diet and the degree of invasiveness and pain of the type of exam. Many gastroenterologists declare that a percentage of patients avoid undergoing colonoscopy even if prescribed by the doctor and already booked.
    In these cases ColoAlert helps to create a sustainable, non-invasive and painless screening strategy, which patients can follow even in the long term without particular efforts.
    It also allows, with a sensitivity of 85% and a specificity of 92%, to achieve an efficacy such as to recommend colonoscopy in cases where it is really required, as well as giving a strong motivation to those patients who are undecided about colonoscopy.

    Genetic Analysis reveals:

    • Human DNA (hDNA)

      The above-threshold amount of human DNA in stools indicates an intensive proliferation of cells. This factor can be associated with a strong inflammation or to the development of polyps / tumoral mass.

    • Biomarker KRAS

      KRAS gene mutations are present in approximately 25% of cancers, particularly 40% of colorectal cancer cases.

      This makes these genetic mutations one of the most linked to cancer.

    • Biomarker BRAF

      BRAF gene mutations are present in about 10% of colorectal cancer. In these cases it is possible that the tumor is of a rare type, resistant to traditional therapies, which makes timely detection even more important.

    La unidad de la prueba Coloalert

    Rilevazione precoce

    El test Coloalert identifica el potencial tumor sin que haya signos de palidez o presencia de sangre oculta en los tejidos. Por lo tanto, es eficaz en todas las fases de desarrollo de la enfermedad.

    100% Indolore

    Práctico y sencillo, con dos dispositivos: un tampón y una fiala para recoger los dos campos de feci en forma rápida y totalmente no invasiva.

    92% de especificidad

    Este indicador estudia la precisión con la que se identifican los pacientes negativos.

    Si el resultado negativo del test Coloalert es realmente fiable.

    3 años de vigencia

    La rapidez con la que se desarrolla una masa tumoral evolutiva varía en función de diferentes factores, como la edad.

    No obstante, el resultado negativo de la prueba Coloalert le permite esperar hasta 3 años antes de volver a realizar el proceso de detección.